Ameritas Investment Partners, Inc. Fate Therapeutics Inc Transaction History

Ameritas Investment Partners, Inc.

$2.86 Billion
Q1 2024

A detailed history of Ameritas Investment Partners, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 8,358 shares of FATE stock, worth $26,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,358

Previous 8,358 -0.0%

Holding current value

$26,912

Previous $31,000 96.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $4,169 - $10,402	2,064 Added 32.79%	8,358 $17,000
Q2 2021 Aug 06, 2021	BUY	$67.25 - $92.52 $6,725 - $9,252	100 Added 1.61%	6,294 $546,000
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $13,999 - $22,775	194 Added 3.23%	6,194 $511,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $3,961 - $10,498	-104 Reduced 1.7%	6,000 $546,000
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $17,364 - $23,125	571 Added 10.32%	6,104 $244,000

Q2 2020 Aug 05, 2020	BUY	$20.21 - $35.23 $6,446 - $11,238	319 Added 6.12%	5,533 $190,000
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $10,390 - $16,086	776 Added 17.49%	5,214 $102,000
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $9,241 - $12,100	-592 Reduced 11.77%	4,438 $90,000
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $12,229 - $17,400	930 Added 22.68%	5,030 $88,000
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $4,750 - $10,382	754 Added 22.53%	4,100 $40,000
Q2 2017 Aug 15, 2017	BUY	N/A	3,346	3,346 $11,000

Others Institutions Holding FATE

# of Institutions

178

Shares Held

124M

Call Options Held

222K

Put Options Held

48.6K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $312M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.

Account

Ameritas Investment Partners, Inc. Fate Therapeutics Inc Transaction History